[144] Agios Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Agios Pharmaceuticals, Inc. (AGIO) has filed a Form 144 indicating a planned sale of restricted securities under Rule 144 of the Securities Act of 1933.

• Securities to be sold: 1,400 shares of AGIO common stock.
• Approximate market value: $56,000 (based on the filer’s calculation).
• Broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8th Floor, New York, NY 10004.
• Estimated sale date: 10 July 2025 on the NASDAQ exchange.
• Shares outstanding: 57,915,199, so the proposed sale represents roughly 0.002% of shares outstanding.
• The shares were acquired via stock-option exercise on 10 July 2025 and will be sold for cash.

No other sales by the reporting person were disclosed for the prior three-month period, and no additional remarks were provided. The filing contains the standard representation that the filer is unaware of any undisclosed material adverse information.

This Form 144 is routine administrative disclosure; the dollar amount and share count are immaterial relative to AGIO’s float, implying minimal impact on market dynamics or insider-sentiment interpretation.

Positive

• None.

Negative

• Minor insider sale could be perceived negatively by some investors, even though the size (0.002% of shares outstanding) is immaterial.

Insights

Securities Analyst

TL;DR: Small insider sale (1,400 shares) worth $56k; negligible versus 58 M share float—limited market impact.

The Form 144 signals intent to sell a fractional 0.002% of AGIO’s outstanding stock. Because the dollar value is only $56k and there is no pattern of recent sales, this looks like a routine liquidity event, likely tied to option exercise. Such filings are common and generally non-impactful unless part of a larger trend, which the document explicitly states is not the case over the last three months. Investors typically view sales below 1% of daily trading volume as noise.

Corporate Governance Expert

TL;DR: Standard Rule 144 notice; compliance disclosure, not a governance red flag.

Form 144 ensures regulatory transparency when affiliates sell restricted stock. The filer affirms no undisclosed negative information and provides full broker details. Absence of a 10b5-1 plan date suggests discretionary timing, but given the minuscule size, it poses no governance concern. The filing confirms AGIO’s internal controls for insider transactions are functioning.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1400	56000.00	57915199	07/10/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	07/10/2025	Stock Option Exercise	Issuer			1400	07/10/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

How many AGIO shares are being sold under this Form 144?

1,400 shares of common stock.

What is the aggregate market value of the proposed sale for AGIO?

The filing lists an aggregate value of $56,000 for the shares.

When is the approximate sale date for the AGIO shares?

The filer indicates an approximate sale date of July 10 2025.

What percentage of Agios Pharmaceuticals’ shares outstanding does this sale represent?

Roughly 0.002% of the 57,915,199 shares outstanding.

Which broker is handling the AGIO share sale under Form 144?

The sale will be executed through Morgan Stanley Smith Barney LLC.

How were the AGIO shares acquired by the seller?

Through a stock-option exercise on July 10 2025.